Roth Capital Reiterates a Hold Rating on Tonix Pharma

By Austin Angelo

In a report released today, Scott Henry from Roth Capital reiterated a Hold rating on Tonix Pharma (NASDAQ: TNXP), with a price target of $0.60. The company’s shares opened today at $0.50, close to its 52-week low of $0.35.

Henry observed:

“We note that the main driver remains the PTSD program.”

According to TipRanks.com, Henry is a 1-star analyst with an average return of -0.6% and a 40.8% success rate. Henry covers the Healthcare sector, focusing on stocks such as Acerus Pharmaceuticals Corporation, Novelion Therapeutics Inc, and Apricus Biosciences Inc.

Tonix Pharma has an analyst consensus of Hold.

Based on Tonix Pharma’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $0 and GAAP net loss of $7.58 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $13.36 million.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNXP in relation to earlier this year. Most recently, in November 2016, Ernest Mario, a Director at TNXP bought 120,000 shares for a total of $48,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. It engages in developing and manufacturing new pharmaceutical products that are used in central nervous system drugs in large and growing markets. It products include TNX-102 SL and TNX-201. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.